Five things for pharma marketers to know: Friday, December 18, 2015



1. GlaxosSmithKline's HIV business unit, ViiV Healthcare, agreed to buy Bristol-Myers Squibb's portfolio of experimental HIV drugs in a deal worth up to $1.46 billion. The portfolio includes fostemsavir which received Breakthrough Therapy designation in July. (Bloomberg)

2. Gilead Sciences will make a potential $2 billion stake in Belgian drugmaker Galapadgos to support the development of rheumatoid arthritis treatment ABT-494. AbbVie exited a partnership with Galapagos in September. ABT-494 is a JAK inhibitor that could compete with Pfizer's Xeljanz. (PMLiVE)

3. The FDA ended a Risk Evaluation and Mitigation Strategy for GlaxoSmithKline's type-2 diabetes drug Avandia. The FDA stated that its continued monitoring found no new safety information. Avandia's REMS program began eight years ago after researchers believed they found an increase in the risk of heart attack associated with the drug. 

4. Samsung is investing heavily in the development and manufacturing of biologics. Samsung BioLogics has made deals with Bristol-Myers Squibb and Roche to produce biologics for both drugmakers while its R&D arm, Samsung Bioepis, is looking for regulatory approval of biosimilars. (WSJ)

5. A new screening test for ovarian cancer may reduce deaths from the disease. Researchers developed a formula that factored in a woman's age and the degree of change in CA125, a tumor marker linked to early-stages of the disease. (NYT)